Business
Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS
29% CR rate observed in R/R AML patients with FLT3 mutation 22% CR/CRh rate observed in R/R AML with spliceosome mutation 45% ORR observed in R/R hrMDS
About this update from Curis, Inc.
[{"type":"text","content":"29% CR rate observed in R/R AML patients with FLT3 mutation\n22% CR/CRh rate observed in R/R AML with spliceosome mutation\n45% ORR observed in R/R hrMDS patients with spliceosome mutation \nCuris to review results during conference call, featuring commentary by Dr. Eric Winer, MD, Dana-Farber Cancer Institute, on Monday, December 12 at 10:00 a.m. ET\nLEXINGTON, Mass., Dec. 12, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced positive updated clinical data from the ongoing open label Phase 1a dose escalation study of emavusertib (CA-4948), a novel, small molecule IRAK-4 inhibitor, as a monotherapy in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or high risk myelodysplastic syndromes (hrMDS) in both targeted and non-targeted populations. Patients in a targeted population are those with disease harboring U2AF1, SF3B1 (collectively \"spliceosome\") or FLT3 mutations. The company also announced positive initial data of emavusertib in combination with venetoclax in patients with AML or hrMDS that enrolled in the combination phase (Phase 1b) of the TakeAim Leukemia study prior to the partial clinical hold placed in April 2022.\n\n \n \n \n \n \n \n\n \n\"We have nearly doubled the size of the targeted patient data set, and continue to see consistent and deep anticancer activity, including additional objective responses. We believe these data suggest a favorable anti-cancer activity compared to therapies currently available for these patients. We are also encouraged by the initial combination data,\" said James Dentzer, President and Chief Executive Officer of Curis. \nAs of October 12, 2022, the total monotherapy data to date represents 24 response evaluable patients with a targeted mutation and 34 response evaluable patients without a targeted mutation. This represents 11 additional patients treated in targeted monotherapy populations and 13 additional patients in the non-targeted monotherapy population. In addition to the monotherapy data, there are 4 patients with AML/hrMDS who have been treated with emavusertib in combination with venetoclax.\nIn Expanded Data Set, Findings Support Earlier Data Presented in June 2021 and January 2022Previous data presented by Curis highlighted prelim...